Abbott's CEO said it is going to take a couple of years to get product launches and revenue growth that the company wants to see from its acquisition of Alere.
Abbott's CFO said he expects mid-single-digit growth from diagnostics in Q1 2018 and mid-to-high single digit growth for the full year.
The three firms each had 510(k) clearances for multiple products from the FDA last month for marketing.
The portable device runs an isothermal amplification assay to detect genetic material from strains of tuberculosis in resource limited areas.
The investment bank noted that Hologic could be the "biggest beneficiary from tax reform" in its coverage with a potential 8 percent benefit to earnings per share.
Abbott's Alinity h-series system integrates a standalone hematology analyzer and slide maker-and-stainer module to enable high-throughput complete blood counting.
There were 58 M&A deals in the diagnostics space during the year, paced by Quest, which announced 12 deals. Abbott's $5.3 billion buy of Alere was the biggest acquisition.
Pacific Toxicology Laboratories has expanded its menu to include fentanyl and its analogues as deaths surge from synthetic opioid overdoses.
Siemens noted that in closing the acquisition of Epocal, the former Alere subsidiary, it has also completed its own blood gas portfolio.